CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: November 5, 2019
Result type: Reports
Project Number: SE0555-000
Product Line: Reimbursement Review

Generic Name: Pegfilgrastim

Brand Name: Lapelga

Manufacturer: Apobiologix

Therapeutic Area: Febrile neutropenia

Indications: Febrile neutropenia

Manufacturer Requested Reimbursement Criteria1: As the preferred pegfilgrastim product to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.

Submission Type: Initial

Project Status: Complete

Biosimilar: Yes

Fee Schedule: Schedule D

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedDecember 14, 2017
Patient group input closedFebruary 09, 2018

- No patient input submission received

Submission receivedFebruary 23, 2018
Submission accepted for reviewMarch 02, 2018
Review initiatedMarch 05, 2018
Draft CDR review report(s) sent to applicantApril 19, 2018
Comments from applicant on draft CDR review report(s) receivedApril 24, 2018
Final CDR review report(s) sent to applicantApril 30, 2018
Final CDR review report(s) postedMay 08, 2018